These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 20660705)

  • 1. TLR9-targeted biodegradable nanoparticles as immunization vectors protect against West Nile encephalitis.
    Demento SL; Bonafé N; Cui W; Kaech SM; Caplan MJ; Fikrig E; Ledizet M; Fahmy TM
    J Immunol; 2010 Sep; 185(5):2989-97. PubMed ID: 20660705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunization of flavivirus West Nile recombinant envelope domain III protein induced specific immune response and protection against West Nile virus infection.
    Chu JH; Chiang CC; Ng ML
    J Immunol; 2007 Mar; 178(5):2699-705. PubMed ID: 17312111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccination of mice using the West Nile virus E-protein in a DNA prime-protein boost strategy stimulates cell-mediated immunity and protects mice against a lethal challenge.
    De Filette M; Soehle S; Ulbert S; Richner J; Diamond MS; Sinigaglia A; Barzon L; Roels S; Lisziewicz J; Lorincz O; Sanders NN
    PLoS One; 2014; 9(2):e87837. PubMed ID: 24503579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Novel Synthetic TLR-4 Agonist Adjuvant Increases the Protective Response to a Clinical-Stage West Nile Virus Vaccine Antigen in Multiple Formulations.
    Van Hoeven N; Joshi SW; Nana GI; Bosco-Lauth A; Fox C; Bowen RA; Clements DE; Martyak T; Parks DE; Baldwin S; Reed SG; Coler RN
    PLoS One; 2016; 11(2):e0149610. PubMed ID: 26901122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Matrix-M™ adjuvanted envelope protein vaccine protects against lethal lineage 1 and 2 West Nile virus infection in mice.
    Magnusson SE; Karlsson KH; Reimer JM; Corbach-Söhle S; Patel S; Richner JM; Nowotny N; Barzon L; Bengtsson KL; Ulbert S; Diamond MS; Stertman L
    Vaccine; 2014 Feb; 32(7):800-8. PubMed ID: 24380682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TLR3- and MyD88-dependent signaling differentially influences the development of West Nile virus-specific B cell responses in mice following immunization with RepliVAX WN, a single-cycle flavivirus vaccine candidate.
    Xia J; Winkelmann ER; Gorder SR; Mason PW; Milligan GN
    J Virol; 2013 Nov; 87(22):12090-101. PubMed ID: 23986602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Supramolecular peptide hydrogel adjuvanted subunit vaccine elicits protective antibody responses against West Nile virus.
    Friedrich BM; Beasley DWC; Rudra JS
    Vaccine; 2016 Nov; 34(46):5479-5482. PubMed ID: 27670075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A recombinant West Nile virus envelope protein vaccine candidate produced in Spodoptera frugiperda expresSF+ cells.
    Bonafé N; Rininger JA; Chubet RG; Foellmer HG; Fader S; Anderson JF; Bushmich SL; Anthony K; Ledizet M; Fikrig E; Koski RA; Kaplan P
    Vaccine; 2009 Jan; 27(2):213-22. PubMed ID: 18996430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy.
    Demento SL; Eisenbarth SC; Foellmer HG; Platt C; Caplan MJ; Mark Saltzman W; Mellman I; Ledizet M; Fikrig E; Flavell RA; Fahmy TM
    Vaccine; 2009 May; 27(23):3013-21. PubMed ID: 19428913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A plant-produced vaccine protects mice against lethal West Nile virus infection without enhancing Zika or dengue virus infectivity.
    Lai H; Paul AM; Sun H; He J; Yang M; Bai F; Chen Q
    Vaccine; 2018 Mar; 36(14):1846-1852. PubMed ID: 29490880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repeated in vivo stimulation of T and B cell responses in old mice generates protective immunity against lethal West Nile virus encephalitis.
    Uhrlaub JL; Brien JD; Widman DG; Mason PW; Nikolich-Zugich J
    J Immunol; 2011 Apr; 186(7):3882-91. PubMed ID: 21339368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy of inactivated West Nile vaccine (WN-VAX) in mice and monkeys.
    Muraki Y; Fujita T; Matsuura M; Fuke I; Manabe S; Ishikawa T; Okuno Y; Morita K
    Virol J; 2015 Apr; 12():54. PubMed ID: 25889682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complex adenovirus-mediated expression of West Nile virus C, PreM, E, and NS1 proteins induces both humoral and cellular immune responses.
    Schepp-Berglind J; Luo M; Wang D; Wicker JA; Raja NU; Hoel BD; Holman DH; Barrett AD; Dong JY
    Clin Vaccine Immunol; 2007 Sep; 14(9):1117-26. PubMed ID: 17634508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunity.
    McDonald WF; Huleatt JW; Foellmer HG; Hewitt D; Tang J; Desai P; Price A; Jacobs A; Takahashi VN; Huang Y; Nakaar V; Alexopoulou L; Fikrig E; Powell TJ
    J Infect Dis; 2007 Jun; 195(11):1607-17. PubMed ID: 17471430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vero cell-derived inactivated West Nile (WN) vaccine induces protective immunity against lethal WN virus infection in mice and shows a facilitated neutralizing antibody response in mice previously immunized with Japanese encephalitis vaccine.
    Lim CK; Takasaki T; Kotaki A; Kurane I
    Virology; 2008 Apr; 374(1):60-70. PubMed ID: 18221765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of chimaeric West Nile virus attenuated vaccine candidate based on the Japanese encephalitis vaccine strain SA14-14-2.
    Li XF; Zhao W; Lin F; Ye Q; Wang HJ; Yang D; Li SH; Zhao H; Xu YP; Ma J; Deng YQ; Zhang Y; Qin ED; Qin CF
    J Gen Virol; 2013 Dec; 94(Pt 12):2700-2709. PubMed ID: 24092759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A DNA vaccine encoding the E protein of West Nile virus is protective and can be boosted by recombinant domain DIII.
    Schneeweiss A; Chabierski S; Salomo M; Delaroque N; Al-Robaiy S; Grunwald T; Bürki K; Liebert UG; Ulbert S
    Vaccine; 2011 Aug; 29(37):6352-7. PubMed ID: 21596075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of West Nile virus infectious DNA and its noninfectious derivatives.
    Seregin A; Nistler R; Borisevich V; Yamshchikov G; Chaporgina E; Kwok CW; Yamshchikov V
    Virology; 2006 Dec 5-20; 356(1-2):115-25. PubMed ID: 16935318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-chain HLA-A2 MHC trimers that incorporate an immundominant peptide elicit protective T cell immunity against lethal West Nile virus infection.
    Kim S; Li L; McMurtrey CP; Hildebrand WH; Weidanz JA; Gillanders WE; Diamond MS; Hansen TH
    J Immunol; 2010 Apr; 184(8):4423-30. PubMed ID: 20212098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimeric dengue 2 PDK-53/West Nile NY99 viruses retain the phenotypic attenuation markers of the candidate PDK-53 vaccine virus and protect mice against lethal challenge with West Nile virus.
    Huang CY; Silengo SJ; Whiteman MC; Kinney RM
    J Virol; 2005 Jun; 79(12):7300-10. PubMed ID: 15919884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.